Remove Engineering Remove Networking Remove Patients Remove Safety
article thumbnail

Leading patient adherence pharmaceutical companies

Pharmaceutical Technology

Failing to adhere to prescribed medication regimens is one of the prime reasons for poor patient health outcomes. Pharmaceutical and healthcare companies are working continuously to improve patient adherence, which also impacts disease control and pharmaceutical industry revenues directly. Patient adherence.

Leads 52
article thumbnail

Eli Lilly reveals plans for new high-tech parenteral manufacturing site

European Pharmaceutical Review

Supporting European parenteral manufacture and supply Alongside expanding the company’s global parenteral product and device manufacturing network, the new facility will support the higher demand for Eli Lilly’s medicines, including its diabetes and obesity portfolio. This includes automation and high-speed manufacturing lines.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

UroMems Announces First-Ever Smart Artificial Urinary Sphincter Implant in a Female Patient

Legacy MEDSearch

UroMems , a global company developing innovative, mechatronics technology to treat stress urinary incontinence (SUI), announced today that it has successfully completed the first-ever implant of the UroActive smart, automated artificial urinary sphincter (AUS) in a female patient. Food and Drug Administration).

article thumbnail

15th Annual Pre-Filled Syringes and Injectable Drug Devices Conference

pharmaphorum

This event will not only bring you key insights you need to expand and enhance your injectable device portfolio but will also give you the opportunity to network with key players throughout the industry. Eleanor Kimber, Principal Device Engineer, GSK. Markus Hemminger, Principal Medical Device Engineer, Roche.

article thumbnail

How one pharma “family business” places patients first

pharmaphorum

And just as a family business thrives on its connection to the community, Chiesi is committed to connecting to the global patient community. We try to have a very long-term orientation because we believe that aligns our objectives very well with the objectives of society and the patients we serve, and it makes us a stable business.”.

article thumbnail

Meeting rising demands of a new radiotheranostic era

European Pharmaceutical Review

Cancer patients critically depend on accurate diagnosis and disease treatment. By reaching cancer cells that have already spread throughout the body, a targeted radiopharmaceutical treatment offers an alternative for patients with advanced cancer when standard lines of treatment, such as chemotherapy, have failed.

article thumbnail

ClearPoint Neuro Announces FDA Clearance for ClearPoint Maestro™ Brain Model

Legacy MEDSearch

This first-generation anatomical segment analysis tool emerged over 10 years ago from research aimed at detecting subtle volumetric and shape abnormalities in patients with mild traumatic brain injury. More importantly, it provides point-based correspondence longitudinally and across patients. About ClearPoint Neuro.

FDA 98